In oncology drug development, using biomarkers to select a study population more likely to benefit from a therapeutic effect is critical to increase the efficiency of a clinical trial in demonstrating ...
The Civilian Oversight Commission is raising concerns about a previously unknown deputy subgroup that oversight officials say uses a logo featuring Nazi-like imagery, according to a memo obtained by ...
Results presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU 2025) Treatment with UGN-102 resulted in durable complete response (CR) rates across subgroups ...
Autonomix (AMIX) Medical announced results from a post-hoc exploratory subgroup analysis of its previously reported first-in-human proof-of-concept study, PoC 1, evaluating the safety and ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback